Oddity, enGene, DoubleDown Price Targets, November 12 2026
Oddity
ODDITY Tech runs online beauty and wellness brands. Almost all of its sales go direct to buyers. Its brands are IL MAKIAGE in cosmetics, SpoiledChild in wellness and METHODIQ in skin care. It reported third-quarter results on Wednesday. Net revenue came to $145.0 million, 2.6% above the $141.3 million consensus. Adjusted earnings were $0.37 a share, against $0.40 a year earlier.
What Drove Oddity’s Quarter
Net revenue shrank 2% from $147.9 million a year earlier. The company had guided to a decline of about 5%. Online direct-to-consumer sales were $138.7 million, or 96% of the total. Other revenue, mostly retail in Israel and marketing affiliates, came to $6.3 million.
Chief financial officer Lindsay Drucker Mann said more than 80% of net revenue came from repeat customers. Repeat orders were stable against a year earlier, she said. First-order revenue was lower by a high-teens percentage, she said. She tied that to a dislocation in the IL MAKIAGE account with the company’s largest advertising partner.
By brand, the company said SpoiledChild posted strong double-digit growth. The company expects it to grow at least 35% this year and approach $350 million in net revenue. METHODIQ grew from the second quarter. Chief executive Oran Holtzman said IL MAKIAGE is lower this year and called its issue “a technical problem with the algorithm.”
The gross margin was 67.4%, against 71.6% a year earlier. Mann pointed to an average order value about mid-single digits lower. Adjusted EBITDA was $22.0 million, against $28.9 million. The company had guided to $18 million to $20 million. Net income was $11.2 million. Oddity ended September with $560.7 million in cash and investments.
Oddity’s New Outlook
Oddity now expects full-year net revenue to shrink about 18.5%, against a 19.0% decline before. It raised its adjusted EBITDA outlook to $32 million to $34 million, from $30 million to $32 million. For the fourth quarter it sees net revenue 10% to 11% lower and adjusted EBITDA of $4 million to $6 million. Holtzman said the goal is to return to growth. He gave no 2027 guidance.
Three Desks Weigh In on Oddity
Youssef Squali of Truist kept Hold and raised his target from $18 to $20 today. Ryan MacDonald of Needham reiterated Hold. Lauren Lieberman of Barclays raised her target to $15.
Oddity’s Record on AnaChart
Oddity draws 9 covering analysts on AnaChart. Their average target is $13.12, with a high of $21 and a low of $8. Ratings split 53.33% Hold, 43.33% Buy and 3.33% Sell. AnaChart’s tracking shows 72.66% of Oddity targets get met. That takes about 194 days on average.
enGene
enGene Therapeutics is a clinical-stage biotech company. Its gene therapies go straight into the bladder and use no virus. Its lead drug is detalimogene, for non-muscle-invasive bladder cancer that no longer responds to BCG treatment. It has no product sales yet. For the quarter ended July 31, its net income was a loss of $32.5 million. Research took $20.1 million of spending. On Wednesday it released new data from the pivotal first cohort of its Phase 2 LEGEND trial.
What Drove enGene’s Update
The cohort enrolled 125 patients with high-risk disease and carcinoma in situ. Of the 120 who could be evaluated, 56% reached a complete response at any time. That compares with 54% in the April analysis. At the 12-month mark, 24% were in complete response, against 13% before. An early estimate put responses lasting a year or more at 43%, against 25%. Median duration of response was 10.1 months.
Also, 97% of evaluable patients had no spread to deeper disease. And 86% had kept their bladder. On safety, 59% had a treatment-related side effect, mostly mild. Grade 3 events were 4%, and 1% stopped treatment.
The company said it agreed with the FDA on key parts of its filing for approval, a Biologics License Application. It expects to start the submission by the end of 2026 and complete it in the first half of 2027. Chief executive Ron Cooper called it “a clear path” to begin before year-end. Detalimogene holds RMAT and Fast Track designations. enGene reported about $245.8 million in cash and marketable securities at October 31, a preliminary unaudited figure.
Two Upgrades on enGene
Yanan Zhu of Wells Fargo upgraded enGene to Overweight from Equal Weight and raised the price target from $2 to $6 today. Allison Bratzel of Piper Sandler upgraded the stock to Overweight from Neutral, with a $4 target. Sean McCutcheon of Raymond James reiterated Outperform and a $4 target.
enGene’s Record on AnaChart
enGene draws 8 covering analysts on AnaChart. Their average target is $11.18. Ratings split 84.21% Buy and 15.79% Hold. AnaChart’s tracking shows 7.41% of enGene targets get met. That takes about 19 days on average.
DoubleDown
DoubleDown Interactive makes free-to-play social casino games, led by DoubleDown Casino. It also runs online gambling sites through SuprNation and owns WHOW Games. DoubleU Games of South Korea owns about 67% of it. It reported third-quarter results on Wednesday. Revenue came to $94.27 million, 1.8% above the $92.63 million consensus.
What Drove DoubleDown’s Quarter
Revenue shrank 1.6% from $95.8 million a year earlier. Social casino revenue was $76.8 million, 3.5% lower. Chief executive In Keuk Kim pointed to a shrinking social casino market. SuprNation’s online gambling revenue grew 7.4% to $17.4 million. The company credited its newest brand, Los Vegas.
Sales made straight to players, outside the app stores, reached $44.6 million. That was 58% of social casino revenue, against 20.9% a year earlier. Meanwhile, operating expenses shrank to $56.8 million from $60.9 million. The company cited lower platform fees. Adjusted EBITDA grew 7.2% to $40.2 million, a 42.7% margin.
Payer conversion was 9.5%, against 7.8%. Average daily revenue per user was $1.44, against $1.39. Monthly revenue per payer was $216, against $272. The company said WHOW players spend less per payer. Profit was $18.4 million, against $32.7 million. Chief financial officer Joe Sigrist pointed to foreign currency losses on dollar assets.
The DoubleU Games Offer
On November 9, DoubleDown signed an agreement under which DoubleU Games offers $16.25 in cash for each American depositary share it does not already own. A special committee backed the deal, and the board approved it. The offer needs a majority of minority holders. DoubleDown ended September with about $545 million in net cash.
Three Desks Weigh In on DoubleDown
Eric Handler of Roth downgraded DoubleDown to Neutral from Buy and raised the price target from $16 to $16.25 today. Alicia Reese of Wedbush raised her target to $16.25. Aaron Lee of Macquarie downgraded DoubleDown to Neutral from Outperform.
DoubleDown’s Record on AnaChart
AnaChart currently counts one covering analyst on DoubleDown, rated Hold. AnaChart’s tracking shows 19.05% of DoubleDown targets get met. That takes about 20 days on average.
What the Performance Matrix Shows
Oddity has the best met ratio of the three, and enGene the lowest. A met Oddity target lands in about 194 days. A met enGene target takes about 19. AnaChart’s first Oddity forecast dates to August 2023. Its first enGene forecast dates to February 2024, and its first DoubleDown forecast to September 2021.
AnaChart tracks every price target against what happened to the stock afterward, desk by desk and analyst by analyst. The ticker pages linked above break out each record by analyst, firm and year. AnaChart’s full data set holds more than 760,000 analyst calls on more than 9,000 tickers, active and delisted. More than 680,000 carry a price target and more than 730,000 carry a rating. It is the second largest database of its kind. The raw file is available through the AnaChart store.
The previous update covered D-Wave, Rigetti and MAA on November 11.
